The News

Maurice Petitou, Head of Preclinical Research & Development at Endotis Pharma, wins the Charles Mentzer Prize for his discoveries on synthetic oligosaccharides in thrombosis

09/07/2009

Parc Biocitech, Paris (France), July 9th, 2009 - Endotis Pharma, a specialty biopharmaceutical company specialized in the discovery and development of synthetic oligosaccharides (« small-glyco drugs »)  for applications in the fields of thrombosis and cancer, today announced that Maurice Petitou PhD (the company's Head of Preclinical Research & Development) was awarded the Charles Mentzer Prize on July 3rd, 2009, for his work on heparin-derived antithrombotics. On this occasion Maurice Petitou presented his research work at the 45th International Medicinal Chemistry Meeting in Orleans, France.

The Charles Mentzer Prize is awarded every two years by the French Society of Medicinal Chemistry.

"It’s a great honor to be awarded by my peers the Charles Mentzer Prize, for my research on heparin-derived antithrombotics. I have devoted my career to the treatment of cardiovascular diseases that affect 300,000 people in France every year", stated Maurice Petitou.

Charles Woler, Endotis Pharma's President and CEO, commented "We are honored and delighted that Maurice Petitou has received such a great distinction - a crowning accomplishment in recognition of his long and fruitful research career. Over the last 4 years, Maurice has provided Endotis Pharma with his scientific skills and unique experience to serve our preclinical and clinical antithrombotic programs on which he focuses all his efforts and those of his teams".

Maurice Petitou joined Endotis Pharma as Head of Preclinical Research & Development in 2005, after 27 years in the pharmaceutical industry. A PhD chemist by training, Maurice Petitou has contributed significantly to the field of heparin research from which come many drugs. He is the inventor of several antithrombotic drugs marketed or in advanced clinical development. He is also the winner of the Galien Prize for Medical Research, the Whistler Prize on carbohydrates and the Leon Velluz Prize from the French Academy of Sciences.

About Endotis Pharma (www.endotis.com)
Endotis Pharma is a biopharmaceutical company dedicated to the discovery and development of small-glyco drugs (heparin / heparan sulphate mimetics) for applications in thrombosis, oncology and a range of other indications. Its powerful discovery engine reduces risk by focusing on proven concepts, and by rationally designing drug candidates with the properties required for commercial success. The value of this platform is demonstrated by the breakthrough Endotis thrombosis franchise of oral and parenteral drugs in clinical and preclinical development, and a promising oncology pipeline. Endotis has 35 employees based in Paris and Lille (France).

Disclaimer: the development of new drug technologies is difficult, erratic and unpredictable. Endotis Pharma’s forecasts and future economic performance depend on research that has yet to be performed and on a number of other factors. The company's future economic performance may differ significantly from that currently forecast.

For more information:

Press contact: Alize RP
Caroline Carmagnol
+33 (0)6 64 18 99 59
caroline@alizerp.com
Juliette Vandenbroucque
+ 33 (0)1 41 22 07 32
juliette@alizerp.com
Investor contact: Endotis Pharma
Charles Woler, Chairman and CEO
charleswoler@endotis.com
Stéphane Degove, CFO
stephanedegove@endotis.com
+33 (0)1 48 46 84 87